Cargando…

SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling

Somewhat counterintuitively, the tyrosine phosphatase SHP-2 (SH2 domain-containing protein tyrosine phosphatase-2) is crucial for the activation of extracellular signal-regulated kinase (ERK) downstream of various growth factor receptors, thereby exerting essential developmental functions. This phos...

Descripción completa

Detalles Bibliográficos
Autores principales: Niogret, Charlène, Birchmeier, Walter, Guarda, Greta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823243/
https://www.ncbi.nlm.nih.gov/pubmed/31708921
http://dx.doi.org/10.3389/fimmu.2019.02468
_version_ 1783464489434218496
author Niogret, Charlène
Birchmeier, Walter
Guarda, Greta
author_facet Niogret, Charlène
Birchmeier, Walter
Guarda, Greta
author_sort Niogret, Charlène
collection PubMed
description Somewhat counterintuitively, the tyrosine phosphatase SHP-2 (SH2 domain-containing protein tyrosine phosphatase-2) is crucial for the activation of extracellular signal-regulated kinase (ERK) downstream of various growth factor receptors, thereby exerting essential developmental functions. This phosphatase also deploys proto-oncogenic functions and specific inhibitors have recently been developed. With respect to the immune system, the role of SHP-2 in the signaling of cytokines relevant for myelopoiesis and myeloid malignancies has been intensively studied. The function of this phosphatase downstream of cytokines important for lymphocytes is less understood, though multiple lines of evidence suggest its importance. In addition, SHP-2 has been proposed to mediate the suppressive effects of inhibitory receptors (IRs) that sustain a dysfunctional state in anticancer T cells. Molecules involved in IR signaling are of potential pharmaceutical interest as blockade of these inhibitory circuits leads to remarkable clinical benefit. Here, we discuss the dichotomy in the functions ascribed to SHP-2 downstream of cytokine receptors and IRs, with a focus on T and NK lymphocytes. Further, we highlight the importance of broadening our understanding of SHP-2′s relevance in lymphocytes, an essential step to inform on side effects and unanticipated benefits of its therapeutic blockade.
format Online
Article
Text
id pubmed-6823243
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68232432019-11-08 SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling Niogret, Charlène Birchmeier, Walter Guarda, Greta Front Immunol Immunology Somewhat counterintuitively, the tyrosine phosphatase SHP-2 (SH2 domain-containing protein tyrosine phosphatase-2) is crucial for the activation of extracellular signal-regulated kinase (ERK) downstream of various growth factor receptors, thereby exerting essential developmental functions. This phosphatase also deploys proto-oncogenic functions and specific inhibitors have recently been developed. With respect to the immune system, the role of SHP-2 in the signaling of cytokines relevant for myelopoiesis and myeloid malignancies has been intensively studied. The function of this phosphatase downstream of cytokines important for lymphocytes is less understood, though multiple lines of evidence suggest its importance. In addition, SHP-2 has been proposed to mediate the suppressive effects of inhibitory receptors (IRs) that sustain a dysfunctional state in anticancer T cells. Molecules involved in IR signaling are of potential pharmaceutical interest as blockade of these inhibitory circuits leads to remarkable clinical benefit. Here, we discuss the dichotomy in the functions ascribed to SHP-2 downstream of cytokine receptors and IRs, with a focus on T and NK lymphocytes. Further, we highlight the importance of broadening our understanding of SHP-2′s relevance in lymphocytes, an essential step to inform on side effects and unanticipated benefits of its therapeutic blockade. Frontiers Media S.A. 2019-10-25 /pmc/articles/PMC6823243/ /pubmed/31708921 http://dx.doi.org/10.3389/fimmu.2019.02468 Text en Copyright © 2019 Niogret, Birchmeier and Guarda. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Niogret, Charlène
Birchmeier, Walter
Guarda, Greta
SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
title SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
title_full SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
title_fullStr SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
title_full_unstemmed SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
title_short SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
title_sort shp-2 in lymphocytes' cytokine and inhibitory receptor signaling
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823243/
https://www.ncbi.nlm.nih.gov/pubmed/31708921
http://dx.doi.org/10.3389/fimmu.2019.02468
work_keys_str_mv AT niogretcharlene shp2inlymphocytescytokineandinhibitoryreceptorsignaling
AT birchmeierwalter shp2inlymphocytescytokineandinhibitoryreceptorsignaling
AT guardagreta shp2inlymphocytescytokineandinhibitoryreceptorsignaling